Loading
A phase 2 trial of Fludarabine, Bendamustine in hodgkin lymphoma, run by Tessa Therapeutics, active and no longer recruiting.
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) is a phase 2 interventional study registered as NCT04268706 by Tessa Therapeutics, with 97 participants planned, started 2021-02-01 and due to reach its primary completion in 2025-05. Interventions recorded: CD30.CAR-T, Fludarabine, Bendamustine. Conditions listed: Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Bendamustine, Fludarabine.
Shares Bendamustine, Fludarabine.
Shares Fludarabine, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Bendamustine, Hodgkin lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/